Zai Lab (NASDAQ:ZLAB) Director Sells $212,650.00 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis sold 8,506 shares of Zai Lab stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the sale, the director directly owned 41,931 shares of the company’s stock, valued at $1,048,275. This represents a 16.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

William Lis also recently made the following trade(s):

• On Monday, June 22nd, William Lis sold 7,040 shares of Zai Lab stock. The shares were sold at an average price of $18.09, for a total transaction of $127,353.60.

Zai Lab Stock Down 0.3%

ZLAB stock opened at $25.95 on Friday. The business’s fifty day moving average is $19.58 and its 200-day moving average is $19.49. The company has a market cap of $2.95 billion, a P/E ratio of -15.18 and a beta of 0.78. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $36.77.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. The company had revenue of $106.31 million for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. Research analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Citigroup raised their price objective on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen downgraded Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.20.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.